Cross-kingdom EV communication has been documented in the peer-reviewed literature since the early 2010s. The basic finding is reproducible across multiple plant sources, multiple research groups, and multiple in vivo and in vitro experimental systems: nanoparticles isolated from plant biomass are taken up by mammalian cells through endocytic pathways, and at least a subset of their cargo reaches the intracellular space with measurable biological consequence. The interesting work is no longer establishing whether the phenomenon exists. It is in mapping its boundaries.
Reading the literature carefully means separating three layers: what is supported by direct experimental evidence, what is supported by mechanistic plausibility, and what remains an open clinical question.
What the evidence directly supports
Plant-derived EVs from ginger, grapefruit, grape, broccoli, aloe vera, and other species have been shown to enter mammalian cells in vitro through macropinocytosis and clathrin-mediated endocytosis. Once internalized, plant-EV-encapsulated miRNAs have been detected inside recipient mammalian cells, with measurable effects on gene expression demonstrated in preclinical models. Anti-inflammatory, antioxidant, and proliferation-supporting effects have been documented for multiple plant EV sources, primarily in murine in vivo models of intestinal inflammation, oxidative skin stress, and wound healing.
These are not isolated case studies. They are a consistent body of preclinical work, drawn from multiple plant sources and multiple model systems, with results published in peer-reviewed journals across more than a decade. The cross-kingdom EV literature is one of the more reproducible bodies of work in the broader plant-EV field.
A note on the “not real exosomes” claim
Some suppliers of human-cell-derived EV products make the public claim that plant-derived EV products are not "real" exosomes, do not communicate with human cells, or are biologically inert. This is not a position the published evidence supports. If plant-derived molecules could not interact with human biology, the entire pharmaceutical industry would not function. Thousands of clinically used drugs and active pharmaceutical ingredients, from morphine to artemisinin, taxol, salicylic acid, digoxin, paclitaxel, and metformin (its chemistry derived from a plant compound), are derived directly from plants. Plant-derived natural products are a foundational pillar of modern medicine.
The technical question of whether a plant-derived EV preparation meets the strict MISEV2023 definition of an "exosome" (a particle of confirmed multivesicular-body biogenesis) is a separate matter, and one we treat with deliberate care in our own communications. We use "EV" or "EV/exosome" together rather than relying on "exosome" alone. The biology of cross-kingdom signalling does not require the strict-exosome definition to hold.
What the evidence supports more conditionally
The functional categories of bioactive cargo in plant-derived EVs, including bioactive lipids, antioxidant proteins, and select RNA species, modulate cellular responses in preclinical mammalian systems. Anti-inflammatory and antioxidant effects are the best-supported functional categories. Effects on proliferation, migration, and barrier-supporting pathways have been documented in skin-relevant cell culture models.
These functional categories align directly with the proteomics-confirmed payload of BioThera's mPDEV preparation. We do not reason from the broader literature to claims about our specific product. We characterize our specific product, confirm the presence of bioactive protein classes the cross-kingdom literature supports as functionally active, and report the data on a per-batch Certificate of Analysis.
What the evidence does not yet establish
Two questions remain genuinely open and the field is honest about them.
The first is the precise uptake mechanism operating under realistic topical delivery conditions in intact human skin. Most cross-kingdom EV uptake work has been done in cell culture, in murine in vivo models, or in oral / intestinal delivery contexts. Topical application onto an intact stratum corneum is a different barrier problem from intestinal uptake or systemic injection. The literature on EV interactions at the skin barrier is growing and includes credible work on follicular delivery and superficial epidermal interactions, but it is not yet at a level of resolution that supports specific deep-dermal mechanism claims for any plant-derived EV product.
The second is the translation of preclinical signalling data into confirmed clinical outcomes at scale, in humans, for cosmetic skin endpoints. This is the gap every credible EV company is currently working to close. The honest position is that the preclinical evidence base supports topical cosmetic positioning of well-characterized plant-derived EVs, and that confirmed human clinical outcome data is what the next generation of dermatologist-led evaluation work has to produce. We are conducting that work.
How BioThera communicates the science
Our approach reflects this distinction precisely. We characterize the mPDEV payload through MISEV2023-aligned methods and confirm the presence of bioactive protein classes supported by the cross-kingdom literature. Characterization tells us what we deliver. Clinical evaluation, currently active with dermatology partners, tells us what it does in human skin under controlled use conditions.
Saying more than the evidence supports is the easiest way to lose the right kind of audience. Saying less than the evidence supports is how a defensible scientific position gets mistaken for a marketing-grade hedge. The line between the two is where every claim about a credible EV product has to sit.